Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
Dana-Farber Cancer Institute discusses what it means to be in remission and the transition into survivorship.
Jamil Rivers, 42, is the board president of METAvivor, a nonprofit breast cancer organization. She is living with metastatic breast cancer.
The report highlights how cancer research is extending and improving lives and includes a special feature on COVID-19 and cancer challenges.
Studies suggest BTK inhibitors and hormone therapy might lessen disease severity and speed recovery.
Selpercatinib, the first drug in its class, shrank tumors in over two thirds of previously treated patients.
The way we develop new treatments for cancer does always lead to better survival time, and rarely leads to better quality of life.
Space travel and chemotherapy affect the body similarly, and yet only astronauts undergo physical conditioning to help them stay strong.
This mix-up may help explain why cancer drugs aren’t always as effective as hoped.
Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.
Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.
Microscopic particles that deliver targeted therapy use drugs, heat, light or other agents to destroy cancerous cells.
New study suggests longer hormone therapy may help prevent cancer recurrence.
New treatment approaches target tumors with shared characteristics, regardless of where they appear in the body.
Verzenio delayed disease progression among women with HR-positive/HER2-negative breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.